Published in Helicobacter on March 01, 1996
Helicobacter pylori. Clin Microbiol Rev (1997) 9.22
Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev (2001) 9.14
Cloning and sequence analysis of two copies of a 23S rRNA gene from Helicobacter pylori and association of clarithromycin resistance with 23S rRNA mutations. Antimicrob Agents Chemother (1997) 3.80
New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol (2008) 2.83
Regular review: treatment of Helicobacter pylori infection. BMJ (2000) 2.73
Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics. Antimicrob Agents Chemother (1998) 1.76
Accurate prediction of macrolide resistance in Helicobacter pylori by a PCR line probe assay for detection of mutations in the 23S rRNA gene: multicenter validation study. Antimicrob Agents Chemother (2001) 1.60
Helicobacter pylori uptake and efflux: basis for intrinsic susceptibility to antibiotics in vitro. Antimicrob Agents Chemother (2000) 1.58
Helicobacter pylori infection. World J Gastroenterol (2000) 1.54
Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut (1998) 1.50
Rapid detection, by PCR and reverse hybridization, of mutations in the Helicobacter pylori 23S rRNA gene, associated with macrolide resistance. Antimicrob Agents Chemother (1999) 1.30
Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolates from patients with gastritis or peptic ulcer disease. J Clin Microbiol (1996) 1.29
Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother (1998) 1.23
16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori. Antimicrob Agents Chemother (2002) 1.21
Increasing the duration of dual amoxicillin plus omeprazole Helicobacter pylori eradication to 6 weeks: a pilot study. J Gastroenterol Hepatol (2012) 1.20
In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657. Antimicrob Agents Chemother (1999) 1.16
Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. Antimicrob Agents Chemother (1999) 1.16
Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands. Emerg Infect Dis (1997) 1.12
Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori. Saudi J Gastroenterol (2010) 1.04
Rapid PCR detection of Helicobacter pylori-associated virulence and resistance genes directly from gastric biopsy material. J Clin Microbiol (1998) 0.92
High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter (2014) 0.91
Genotypic characterization of clarithromycin-resistant and -susceptible Helicobacter pylori strains from the same patient demonstrates existence of two unrelated isolates. J Clin Microbiol (1998) 0.90
Sensitivity of amoxicillin-resistant Helicobacter pylori to other penicillins. Antimicrob Agents Chemother (1999) 0.88
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly. Gastroenterol Clin North Am (2015) 0.87
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy. Am J Gastroenterol (2016) 0.87
Dual proton pump inhibitor plus amoxicillin as an empiric anti-H. pylori therapy: studies from the United States. J Gastroenterol (2010) 0.87
Helicobacter pylori is not eradicated after triple therapy: a nested PCR based study. Biomed Res Int (2014) 0.86
Helicobacter pylori infection in hemodialysis patients: susceptibility to amoxicillin and clarithromycin. World J Gastroenterol (2005) 0.85
Subpopulations of Helicobacter pylori are responsible for discrepancies in the outcome of nitroimidazole susceptibility testing. Antimicrob Agents Chemother (1999) 0.84
Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol (2016) 0.82
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Dig Dis Sci (2000) 0.82
Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model. BMJ (1998) 0.76
Helicobacter Pylori. Curr Treat Options Gastroenterol (1999) 0.76
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. World J Gastroenterol (2005) 0.75
The Helicobacter pylori eradication in the group receiving standard -dose and group continue taking amoxicillin for 4 weeks; a clinical trial study. Gastroenterol Hepatol Bed Bench (2015) 0.75
Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. Arch Dis Child (1999) 0.75
Pharmacokinetic interactions between ilaprazole and clarithromycin following ilaprazole, clarithromycin and amoxicillin triple therapy. Acta Pharmacol Sin (2012) 0.75
Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series. Medicine (Baltimore) (2016) 0.75
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. Dig Dis Sci (1998) 0.75
Helicobacter pylori antibody responses in association with eradication outcome and recurrence: a population-based intervention trial with 7.3-year follow-up in China. Chin J Cancer Res (2017) 0.75
Failure of optimized dual proton pump inhibitor amoxicillin therapy: What now? Saudi J Gastroenterol (2017) 0.75
Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet (1990) 9.49
Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology (1988) 8.27
Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut (1999) 7.14
The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med (1995) 6.73
Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group. Lancet (1999) 5.27
Identification of Campylobacter pyloridis isolates by restriction endonuclease DNA analysis. J Clin Microbiol (1986) 5.15
The endoscopic assessment of esophagitis: a progress report on observer agreement. Gastroenterology (1996) 4.69
Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet (1993) 4.55
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology (1995) 4.39
Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology (1989) 4.23
Functional gastroduodenal disorders. Gut (1999) 3.74
Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol (1994) 3.22
Randomised trial of endoscopic balloon dilation versus endoscopic sphincterotomy for removal of bileduct stones. Lancet (1997) 3.12
Needle-knife sphincterotomy as a precut procedure: a retrospective evaluation of efficacy and complications. Endoscopy (1996) 3.12
Sonic hedgehog regulates gastric gland morphogenesis in man and mouse. Gastroenterology (2001) 2.85
Recurrent massive haematemesis from Dieulafoy vascular malformations--a review of 101 cases. Gut (1986) 2.74
Regular review: treatment of Helicobacter pylori infection. BMJ (2000) 2.73
Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol (1996) 2.73
The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis (1996) 2.66
Genotypical variation of Campylobacter pylori from gastric mucosa. J Clin Microbiol (1990) 2.55
Long-term follow-up after endoscopic sphincterotomy for bile duct stones in patients younger than 60 years of age. Gastrointest Endosc (1996) 2.54
Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut (1998) 2.38
The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology (1999) 2.37
Collagenous sprue--an unrecognized type of malabsorption. N Engl J Med (1970) 2.21
Equally high prevalences of infection with cagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol (1997) 2.18
Heterogeneous Helicobacter pylori isolates from members of a family with a history of peptic ulcer disease. Gastroenterology (1996) 2.17
A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther (1999) 2.14
Treatment of bile duct lesions after laparoscopic cholecystectomy. Gut (1996) 2.12
Prevalence of vacuolating cytotoxin production and distribution of distinct vacA alleles in Helicobacter pylori from China. J Infect Dis (1998) 2.09
Self-expanding metal stents in benign biliary strictures due to chronic pancreatitis. Endoscopy (2004) 2.08
Oral cimetidine in reflux esophagitis: a double blind controlled trial. Gastroenterology (1978) 2.07
[Obstructive jaundice after surgery of the biliary tract, a benign stricture or not?]. Ned Tijdschr Geneeskd (2004) 2.05
[Changed diagnosis and treatment of hepatocellular carcinoma]. Ned Tijdschr Geneeskd (1996) 2.04
Intestinal metaplasia and Helicobacter pylori: an endoscopic bioptic study of the gastric antrum. Gut (1992) 1.96
Increased colorectal cancer risk in first-degree relatives of patients with hyperplastic polyposis syndrome. Gut (2010) 1.94
HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut (1999) 1.94
14C-urea breath test in C pylori gastritis. Gut (1989) 1.89
Incidence and clinical findings of benign, inflammatory disease in patients resected for presumed pancreatic head cancer. Gastrointest Endosc (1997) 1.88
Time trends in gastric carcinoma: changing patterns of type and location. Am J Gastroenterol (1992) 1.88
cagA-positive Helicobacter pylori populations in China and The Netherlands are distinct. Infect Immun (1998) 1.84
Gastric non-Hodgkin lymphomas of mucosa-associated lymphoid tissue are not associated with more aggressive Helicobacter pylori strains as identified by CagA. Am J Clin Pathol (1996) 1.84
Endoscopic palliative treatment in pancreatic cancer. Gastrointest Endosc (1986) 1.84
Outcome of palliative biliary and gastric bypass surgery for pancreatic head carcinoma in 126 patients. Br J Surg (1997) 1.84
Analysis of the lympho-plasmacytic infiltrate in Crohn's disease with special reference to identification of lymphocyte-subpopulations. Gut (1976) 1.83
Biliary endoprostheses in elderly patients with endoscopically irretrievable common bile duct stones: report on 117 patients. Gastrointest Endosc (1995) 1.82
Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol (1996) 1.80
A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology (1997) 1.79
Development of a new dyspepsia impact scale: the Nepean Dyspepsia Index. Aliment Pharmacol Ther (1999) 1.76
Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology (1988) 1.75
Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn's disease. Gastroenterology (1999) 1.74
Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. Eur J Gastroenterol Hepatol (1995) 1.74
Impaired quality of life 5 years after bile duct injury during laparoscopic cholecystectomy: a prospective analysis. Ann Surg (2001) 1.71
Endosonography and computed tomography of esophageal carcinoma. Preoperative classification compared to the new (1987) TNM system. Gastroenterology (1989) 1.70
Twenty-four-hour pH measurements in morbid obesity: effects of massive overweight, weight loss and gastric distension. Eur J Gastroenterol Hepatol (1996) 1.70
Acute upper gastrointestinal bleeding in the Amsterdam area: incidence, diagnosis, and clinical outcome. Am J Gastroenterol (1997) 1.69
Intragastric balloon in the treatment of super-morbid obesity. Double-blind, sham-controlled, crossover evaluation of 500-milliliter balloon. Gastroenterology (1990) 1.67
Effect of Helicobacter pylori eradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology (1997) 1.67
Impaired anamnestic cellular immune response in patients with Crohn's disease. Gut (1975) 1.65
A patient with osteomalacia as single presenting symptom of gluten-sensitive enteropathy. J Intern Med (1992) 1.64
Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol (2011) 1.63
Incidence of benign lesions in patients resected for suspicious hilar obstruction. Br J Surg (2001) 1.62
Model bile and bile salts accelerate mucin secretion by cultured dog gallbladder epithelial cells. Gastroenterology (1995) 1.61
What an endoscopist should know about immunoglobulin-G4-associated disease of the pancreas and biliary tree. Endoscopy (2011) 1.61
Benign biliary strictures. Surgery or endoscopy? Ann Surg (1993) 1.59
Intestinal endotoxemia. Clinical significance. Gastroenterology (1988) 1.59
Loss of E-cadherin expression in early gastric cancer. Histopathology (1999) 1.59
Intragastric balloons for morbid obesity: results, patient tolerance and balloon life span. Br J Surg (1990) 1.58
Four years experience with short term stenting in primary sclerosing cholangitis. Am J Gastroenterol (1999) 1.57
The potential diagnostic use of K-ras codon 12 and p53 alterations in brush cytology from the pancreatic head region. J Pathol (1998) 1.56
Sulindac targets nuclear beta-catenin accumulation and Wnt signalling in adenomas of patients with familial adenomatous polyposis and in human colorectal cancer cell lines. Br J Cancer (2004) 1.54
Delayed gastric emptying after standard pancreaticoduodenectomy versus pylorus-preserving pancreaticoduodenectomy: an analysis of 200 consecutive patients. J Am Coll Surg (1997) 1.52
Follow-up study of individuals with untreated Campylobacter pylori-associated gastritis and of noninfected persons with non-ulcer dyspepsia. J Infect Dis (1988) 1.52
Bile duct injury after laparoscopic cholecystectomy: the value of endoscopic retrograde cholangiopancreatography. Gut (1993) 1.52
Clogging of biliary endoprostheses: a new perspective. Gut (1990) 1.52
Early diagnosis and prevention of sporadic colorectal cancer. Endoscopy (2001) 1.51
Impaired drinking capacity in patients with functional dyspepsia: relationship with proximal stomach function. Gastroenterology (2001) 1.51
Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy (1999) 1.51
Palliative treatment of obstructive jaundice by transpapillary introduction of large bore bile duct endoprosthesis. Gut (1982) 1.51
Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication. Gut (1998) 1.50
A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule. Am J Gastroenterol (2000) 1.50
A randomized trial of endoscopic balloon dilation and endoscopic sphincterotomy for removal of bile duct stones in patients with a prior Billroth II gastrectomy. Gastrointest Endosc (2001) 1.49
Validation of the Rockall risk scoring system in upper gastrointestinal bleeding. Gut (1999) 1.49
Piperacillin to prevent cholangitis after endoscopic retrograde cholangiopancreatography. A randomized, controlled trial. Ann Intern Med (1996) 1.48